Table 2.

Clinical and Biochemical Characteristics of the Patients With and Without Somatic USP8 Mutations

	Somatic USP8 Mutation, n = 13 (31.0%)	No Somatic USP8 Mutation, n = 29 (50.0%)	P
Mean age at diagnosis, y	15.1 ± 2.1	13.1 ± 3.6	0.03
Female sex, n (%)	11 (84.6)	16 (55.2)	0.07
Follow up duration, mo	21.1 ± 22.4	27.7 ± 4.8	0.6
Ethnicity
Asian	0	1 (3.4)	0.1
African American	2 (15.4)	2 (6.9)
Unknown	4 (30.8)	2 (6.9)
Caucasian	7 (53.8)	24 (82.8)
Anthropometric data
BMI z score	1.5 ± 1.0	2.1 ± 0.7	0.02
BMI z score ≥2, n (%)	5 (38.5)	22 (75.9)	0.02
Height z score	−1.1 ± 1.2	−1.0 ± 1.1	0.9
Height z-score ≤−0.5, n (%)	10 (76.9)	21 (72.4)	0.8
Tumor characteristics
Diameter, mm	8.0 ± 7.0	5.4 ± 5.4	0.2
Diameter ≥5 mm, n (%)	9 (69.2)	13 (44.8)	0.1
Invasion of cavernous sinus, n (%)	2 (15.4)	2 (6.9)	0.4
Biochemical data
Midnight cortisol, μg/dL	19.5 ± 7.4	18.7 ± 15.7	0.9
Plasma ACTH, pg/mL	47.7 ± 30.1	82.2 ± 94.3	0.2
24 hour UFC, μg/24 h	396 ± 466	468 ± 671	0.7
Time from first symptoms to diagnosis
Time, y	2.1 ± 1.2	2.1 ± 1.7	0.9
≥3 y, n (%)	4 (30.8)	6 (20.7)	0.5
Treatment
Recurrence or failure to cure, n (%)	6 (46.2)	3 (10.3)	0.009